1. Low-Dose Gamma Knife Radiosurgery for Acromegaly.
- Author
-
Pai FY, Chen CJ, Wang WH, Yang HC, Lin CJ, Wu HM, Lin YC, Chen HS, Yen YS, Chung WY, Guo WY, Pan DH, Shiau CY, and Lee CC
- Subjects
- Acromegaly etiology, Adenoma complications, Adenoma pathology, Adolescent, Adult, Aged, Female, Follow-Up Studies, Growth Hormone-Secreting Pituitary Adenoma complications, Growth Hormone-Secreting Pituitary Adenoma pathology, Humans, Male, Middle Aged, Neoplasm Recurrence, Local epidemiology, Retrospective Studies, Sweden, Treatment Outcome, Young Adult, Acromegaly therapy, Adenoma therapy, Growth Hormone-Secreting Pituitary Adenoma therapy, Radiosurgery methods
- Abstract
Background: Remission rate is associated with higher dose of Gamma Knife Radiosurgery (GKRS; Gamma Knife: Elekta AB, Stockholm, Sweden) for acromegaly, but the dose ≥25 Gy is not always feasible when the functioning adenoma is close to optic apparatus., Objective: To evaluate the efficacy and safety of low-dose (<25 Gy) GKRS in the treatment of patients with acromegaly., Methods: Single-center retrospective review of acromegaly cases treated with GKRS between June 1994 and December 2016. A total of 76 patients with the diagnosis of acromegaly who were treated with low-dose GKRS were selected for inclusion. Patients were treated with a median margin dose, isodose line, and treatment volume of 15.8 Gy, 57.5%, and 4.8 mL, respectively. Any identifiable portion of the optic apparatus was limited to a radiation dose of 10 Gy. All patients underwent full endocrine, ophthalmological, and imaging evaluation prior to and after GKRS treatments, and results of these were analyzed., Results: Biochemical remission was achieved in 33 (43.4%) patients. Actuarial remission rates were 20.3%, 49.9%, and 76.3% at 4, 8, and 12 yr, respectively. Absence of cavernous sinus invasion (P = .042) and lower baseline insulin-like growth factor-1 levels (P = .019) were significant predictors of remission. New hormone deficiencies were found in 9 (11.8%) patients. Actuarial hormone deficiency rates were 3%, 14%, and 22.2% at 4, 8, and 10 yr, respectively. Two (2.6%) patients who achieved initial remission experienced recurrence. No optic complications were encountered., Conclusion: Reasonable remission and new hormone deficiency rates can be achieved with low-dose GKRS for acromegaly. These rates may be comparable to those with standard GKRS margin doses., (Copyright © 2018 by the Congress of Neurological Surgeons.)
- Published
- 2019
- Full Text
- View/download PDF